|View printer-friendly version|
|May 05, 2006 1:39 p.m.|
|Teva Announces Global In-Market First Quarter Sales of its Blockbuster Copaxone® Increased 29% to $329 Million|
Jerusalem, Israel, May 5, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached a record $329 million in the first quarter ended March 31, 2006. Once again, Copaxone® was the fastest growing multiple sclerosis (MS) therapy worldwide, with a growth of 29% in sales over the comparable quarter of 2005.